期刊文献+

高纯度尿促性腺激素对IVF-ET妊娠结局的影响 被引量:1

The influence of highly purified HMG on pregnancy outcome in vitro fertilization
原文传递
导出
摘要 目的:探讨体外受精-胚胎移植(IVF-ET)超促排卵周期中应用高纯度尿促性腺激素(HP-HMG,贺美奇)对妊娠结局的影响。方法:回顾性分析117个IVF-ET周期,根据超促排卵周期中是否使用HP-HMG将其分为两组,A组(n=63)应用果纳芬(r-FSH,重组卵泡刺激素),B组(n=54)加用贺美奇,比较两组妊娠率、流产率、着床率、持续妊娠率和持续着床率。结果:两组鲜胚移植周期妊娠率、流产率、着床率、持续妊娠率和持续着床率比较差异有统计学意义(P<0.05);两组冻胚移植周期妊娠率和着床率比较差异无统计学意义(P>0.05),而流产率、持续妊娠率和持续着床率比较差异有统计学意义(P<0.05)。结论:长方案超促排卵适时加用HP-HMG可以改善胚胎质量和子宫内膜容受性,提高持续妊娠率和持续着床率,降低流产率。 Objective:To study the influence of highly purified HMG on pregnancy outcome in vitro fertilization.Methods:117 patients(retrospective study)underwent IVF-ET cycles were divided into two groups.The patients of group A(n=63) were stimulated with r-FSH,the patients of group B(n=52) were stimulated with r-FSH and HP-HMG.The contrast pregnancy rate,miscarriage rate,implantation rate,ongoing pregnancy rate and ongoing implantation rate between group A and group B were compared.Results:There were statistical significant differences(P0.05) between group A and group B in pregnancy rate,miscarriage rate,implantation rate,ongoing pregnancy rate and ongoing implantation rate in fresh embryo transfer cycles,and there were no statistical differences(P0.05) in pregnancy rate and implantation rate while statistical significant differences(P0.05) in miscarriage rate,ongoing pregnancy rate and ongoing implantation rate in frozen embryo transfer cycles.Conclusion:To supplement HP-HMG to r-FSH in COH(controlled ovarian hyperstimulation) is useful to improve quality of embryos and inner membrance receptivity,and increases ongoing pregnancy rate and ongoing implantation rate and decreases miscarriage rate.
作者 李萍
出处 《中国妇幼保健》 CAS 北大核心 2011年第20期3133-3134,共2页 Maternal and Child Health Care of China
关键词 高纯度尿促性腺激素 妊娠率 流产率 着床率 持续妊娠率 持续着床率 Highly purified HMG Pregnancy rate Miscarriage rate Implantation rate Ongoing pregnancy rate Ongoing implantation rate
  • 相关文献

参考文献3

  • 1Barufl'i RL, Mauri AL, Petersen CG, et al. rLH supplementation to rF- SH during induced ovarian stimulation in the GnRH - a protocol. A meta -analysis [J] . J Assist Reprod Genet, 2007, 14 (1) : 12.
  • 2Nyboe Andersen A, Devroey P, Arce J -C. Clinical outcome foUowing stimulation with highly purified HMG or recombinant FSH in patients un- dergoing IVF: a randomized assessor- blind controlled trial [J] . Hum Reprod, 2006, 21 (12): 3217.
  • 3European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle - Stimulating Hormone. Efficacy and safety of high- ly purified menotropin versus recombinant follicle - stimulating hormone in vitro fertilization/intracytoplasmic sperm injection cycles: a random- ized, comparative trial [J] . Fertility and Sterility, 2002, 78 ( 3 ) : 520.

同被引文献21

  • 1陈新娜,乔杰,何方方,王树玉,王颖.高纯度尿促性素和普通尿促性素促排卵效果[J].中国生育健康杂志,2005,16(4):205-208. 被引量:8
  • 2王颖,陈新娜,金清,罗莉,范燕宏,王海燕,乔杰.不同促排卵方案排卵结局和不同受精方式妊娠结局的相关因素探讨[J].生殖与避孕,2006,26(1):25-31. 被引量:10
  • 3Chappel SC, Howles C. Reevaluation of the roles ofluteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod, 1991, 6(9):1206-12.
  • 4Humaidan P, Bungnm L, Bungum M, et al. Ovarian response and pregnancy outcome related to mid-follicular LH levels inwomen undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod, 2002, 17(8):2016-21.
  • 5Pezzuto A, Ferrari B, Coppola F, et al. LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecol Endocrinol, 2010, 26(2):118-24.
  • 6Matorras R, Prieto B, Exposito A, et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online, 2009, 19(6):879-87.
  • 7The Istanbul consensus workshop on embryo assessment. Proceedings of an expert meeting. Hum Reprod, 2011, 26(6): 1270-83.
  • 8Filicori M, Cognigni GE, Gamberini E, et al. Efficacy of low- dose human chorionic gonadotropin alone to complete con- trolled ovarian stimulation. Fertil Steril, 2005, 84(2):394-401.
  • 9Blockeel C, De Vos M, Verpoest W, et al. Can 200 IU ofhCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study. Hum Reprod, 2009, 24(11):2910-6.
  • 10Ferrell R J, O'Connor KA, Holman DJ, et al. Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in luteinizing hormone and follicle- stimulating hormone with age. Menopause, 2007, 14(1):29-37.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部